A Phase 1b, Randomized, Double-Blind, Placebo-Controlled, Safety, Tolerability and Pharmacokinetic Study of Multiple Rising Doses of MLN9708 for the Treatment of Subjects With ISN / RPS Class III or IV Lupus Nephritis
Phase of Trial: Phase I
Latest Information Update: 09 Apr 2019
Price : $35 *
At a glance
- Drugs Ixazomib (Primary)
- Indications Lupus nephritis
- Focus Adverse reactions
- Sponsors Takeda
- 25 Jan 2018 Status changed from recruiting to discontinued.
- 06 Feb 2017 Planned End Date changed from 1 Feb 2017 to 1 Jun 2018.
- 06 Feb 2017 Planned primary completion date changed from 1 Feb 2017 to 1 Jun 2018.